Allowing Greater Access to Safe and Effective Contraception Act

Summary

Requires the Department of Health and Human Services/FDA to give priority review and waive certain user fees for supplemental drug applications that would make routine oral contraceptives available over the counter for people aged 18 and older, while keeping such products prescription-only for those under 18. Also directs the Government Accountability Office to report to Congress within one year quantifying federal spending on contraception reimbursement, stocking, training, and patient education over the prior 15 years.

• HHS/FDA must give priority review to supplements seeking OTC routine oral contraceptive status for people 18+.
• The priority-review requirement excludes emergency contraceptives and drugs also approved for induced abortion.
• FDA user fees for these eligible supplemental applications must be waived.
• Drugs remain prescription-only for individuals under 18.
• The priority-review and fee-waiver rules cover supplements already pending at enactment and those filed later.
• GAO must report to Congress within one year on federal contraception-related spending over the prior 15 years.
• The GAO study must account for spending across Medicare, Medicaid, IHS, ACA Exchanges, FQHCs, Title X, TANF, and TRICARE.
• No new funding appropriation is included; the bill changes regulatory review priorities and directs a federal study.